Ig repertoire in tumor-infiltrating B cells in metastatic HER2-positive breast cancer (mouse model)
Official title: Immunoglobulin Repertoire Analysis of Tumor Infiltrating B cells in a Metastatic HER2 Positive Breast Cancer Mouse Model
Funded at Texas Southern University · NIH-11413688 · Data updated 2026-11-12
Scientists will study how antibodies from immune cells inside HER2-positive breast tumors behave in a mouse model to understand potential new ways to fight the cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Southern University NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 4, 2025 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $156,877 |
| NIH project number | 5R16GM159781-02 |
| Project ID | NIH-11413688 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with HER2-positive breast cancer whose tumors show immune cell activity or who have donated tumor samples for ig repertoire studies in related projects.
✕Less likely to help
Patients without HER2-positive breast cancer or without tumor-infiltrating B cell activity may not benefit from these findings.
What this research studies
This project looks at the antibodies produced by tumor-infiltrating B cells in a metastatic HER2-positive breast cancer mouse model. Researchers will analyze immunoglobulin repertoires and identify public Ig sequences that may help suppress tumors. The study leverages mouse models and existing human data to explore how these antibodies relate to survival and metastasis. The goal is to uncover mechanisms that could guide future therapies or biomarkers for patients with HER2-positive breast cancer.
Why it matters
Potential benefit: If successful, the work could reveal antibody-based approaches or targets that help control metastasis and improve outcomes for HER2-positive breast cancer patients.
How similar studies have gone: Previous research has linked tumor-infiltrating B cells and immunoglobulins to cancer outcomes, supporting potential translational value but ongoing work is needed for applicability to humans.
Where this research is happening
-
Texas Southern University
Houston, United States Active
Researchers
- Principal investigator: Zhang, Yun — Texas Southern University
- Study coordinator: Zhang, Yun
Related research
Other NIH-funded projects on the same topics.
-
Enhancing HER2-targeted therapy for resistant breast cancer
This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.
-
Prolactin signaling and brain metastasis in HER2-positive breast cancer
Researchers are studying how prolactin signals help HER2-positive breast cancer cells grow in the brain, with the goal of finding new ideas to prevent brain metastases.
-
XoLacta adjuvant therapy to reduce radiation side effects during HER2-positive breast cancer treatment
A new milk-derived therapy called XoLacta aims to lessen radiation-related side effects for people undergoing treatment for HER2-positive breast cancer.
-
Autophagy and vesicle trafficking linked to HER2+ breast cancer progression
A cancer research project aims to understand how cell recycling processes and vesicle movement affect HER2-positive breast cancer, with potential implications for metastasis and resistance to therapy.
-
XoLacta to reduce radiation side effects in HER2-positive breast cancer
XoLacta, a milk-derived therapy given during radiation, aims to help people with HER2-positive breast cancer heal better and have fewer side effects.
-
Why some HER2-positive breast cancers survive targeted therapy
This project looks for the specific cancer cells that survive HER2-targeted drugs in people with HER2-positive breast cancer to find ways to stop drug resistance.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.